Barcode Diagnostics

User-friendly, Safe and Cost-Effective Organ Removal for Laparoscopic GYN Surgery

About Us

Ark Surgical Ltd. is a privately held Israeli medical device company developing a device for facilitating safe and simple laparoscopic organ removal in GYN surgery in the second most common procedure in women`s health. The company was founded by physicians and experts in the field of medical device development with hands-on experience in the clinical setting dedicated to improving the provision of surgical care to the benefit of women worldwide.

Clinical Need

Every third woman in the U.S. will have a uterus removal procedure by the age of 65. Ark Surgical has developed a device that allows this procedure to be performed laparoscopically rather than by open surgery. Laparoscopic surgery is currently the standard of care for many surgical procedures as it is performed through a small incision in an outpatient procedure (no overnight stay), offers less pain, smaller scar, faster recuperation and fewer complications. Despite the clear benefits of laparoscopic surgery, is currently used less frequently for GYN procedures due to the fear of spread of cancer throughout the body during the surgery. This means that each year 1.5 million women worldwide may undergo open surgery that is associated with large painful 12cm incisions, long hospitalization, complications and even death.  


Ark Surgical’s LapBox next generation containment system encapsulates the uterus in a double wall chamber during the surgical procedure. The single-use device prevents the spread of blood, tissue and even cancer cells in the patient.
LapBox has been developed to be a simple to use and safe solution. Based on the enthusiastic feedback from leading surgeons in the U.S. and Europe who have expressed interest in serving as initial centers of excellence upon market launch, LapBox is expected to be widely adopted in the market. To date, no device for this problem has gained broad market adoption due to their cumbersome mode of operation and safety concerns, leaving a significant unaddressed clinical need which LapBox will fill.
LapBox allows hysterectomy to be performed laparoscopically benefitting patients and healthcare providers. The device is expected to shorten hospitalization stays by 300%, save hundreds of millions of dollars to hospitals and insurers and save the lives of 4,500 women every year.

Key benefits:
• User-friendly, rapid set up and use
• Enhanced safety due to the double layer chamber
• Enables manual or power morcellation

LapBox is currently in clinical use as part of a First in Human clinical study in Israel. The Company expects to launch the device in the US during the second half of 2021.


Intellectual Property

The Company has filed 3 patent applications around the world covering the device’s unique concept and structure. 

The Market 

Approximately 600,000 hysterectomies are performed annually in the US alone with the worldwide number estimated at 1.5 million procedures. This offers an estimated market potential for the device of over $500M annually. Other procedures in Urology and General Surgery will be targeted at a later stage.

The Team

Stav Tori, CEO - Experienced medical device professional with 10 years' experience in developing, manufacturing and clinical testing of medical implants and devices for several biomedical companies such as Carbo-Fix Orthopedics, NMB Medical and Disc-O-Tech.  

Abraham Yaari, Co-founder & Medical Director - Graduated in 1990 from the Hebrew University, Jerusalem, and Specialized in Obstetrics and Gynecology in New York and then practiced in Connecticut. Experienced laparoscopic surgeon. Currently affiliated with Hillel Yaffe Hospital.

Aaron Feldman, Co-founder & Director - Seasoned medical device entrepreneur and manager. Served as CEO of Rafael Medical Technologies and CardioFlow. Currently director of business development of MST – Medical Surgery Technologies and co-founder of Restore Medical (Incentive incubator) and FetalEase Ltd.

Zohar Gendler,  Director  - Managing Partner & CEO of NGT3VC. Former CEO & director of Beta-O2 Technologies (developed proprietary implantable bio-artificial pancreas). Served as CEO of the Technion Technological Incubator for 11 years. Led the establishment and investment in 53 companies, such as Prolor Biotech (sold to OPKO, NYSE: OPK, for $480M), Mazor (NASDAQ: MZOR), ReWalk (NASDAQ: RWLK), Corindus (NASDAQ: CVRS), Regentis, and many others.

Medical Advisory Board

Prof. Moti Goldenberg, MD - Head of the Gynecological Department at Sheba Medical Center. Head consultant at Assuta Medical Center and Associate Professor at the Sackler School of Medicine.Member of the ESGE, AAGL, the Israeli Endoscopic Society and the IRCAD International advisory board.

Prof. Michael Stark - Leading European GYN surgeon and consultant to companies in the medical device field including surgical robotics. Adjunct professor at the Moscow Institute of Physics and Technology. Currently serves as President of NESA, the New European Surgical Academy.

Hugh S. Taylor, MD - Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology; Chair of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine; Chief of Obstetrics and Gynecology, Yale-New Haven Hospital.

Yuval Kaufman, MD - Senior Consultant at the Department of Obstetrics & Gynecology at Carmel Medical Center in Haifa, Israel and at Assuta Private Hospital in Haifa, Israel. He is a Cum Laude Alumni of the Technion Israeli Institute for Technology.

Contact Us 

Stav Tori  , CEO, ARK SURGICAL Ltd.

NGT3 (Next Generation Technologies ) Incubator

Wadi El Haj 13 Nazareth

P.O Box 1252 Nazareth Illit  1711102 ,

Israel Cellular: +972-52-3594441

Work:     +972-4-6098623

Fax:         +972-4-6098611

Email:     Info@ARK-SURGICAL.com


Investors - Contact Us

Entrepreneurs - Contact Us